Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Rationale: Renal fibrosis is the terminal manifestation of chronic and irreversible renal disease.Effective therapies other than dialysis are extremely limited.In this study, we investigated the potential effects of targeting elevated interleukin-6 (IL-6) levels in the treatment of renal fibrosis.Methods: Fc-gp130 was used to specifically block IL-6 trans-signaling.Unilateral ureteral occlusion (UUO) and ischemia reperfusion (IR) mouse models were constructed to investigate the therapeutic effect of Fc-gp130 on renal fibrosis.The role of IL-6 trans-signaling and phosphorylation of signal transducer and activator of transcription (STAT) 3 in regulating fibroblast accumulation and extracellular matrix protein deposition were evaluated in cell experiments and mouse models. Results:The kidneys of mice with UUO were found to have elevated soluble IL-6 receptor (sIL-6R) levels in the progression of fibrosis.Fc-gp130 attenuated renal fibrosis in mice, as evidenced by reductions in tubular atrophy and the production of extracellular matrix protein.Blockade of IL-6 trans-signaling with Fc-gp130 also reduced inflammation levels, immune cell infiltration, and profibrotic cytokines expression in renal tissue, with decreased STAT3 phosphorylation and reduced fibroblast accumulation in the renal tissue.In vitro, Fc-gp130 also reduced the phosphorylation of STAT3 induced by transforming growth factor (TGF)-β1 in fibroblasts.Furthermore, the therapeutic effect of Fc-gp130 was confirmed in a model of acute kidney injury-chronic kidney disease.Conclusion: Overall, IL-6 trans-signaling may contribute to crucial events in the development of renal fibrosis, and the targeting of IL-6 trans-signaling by Fc-gp130 may provide a novel therapeutic strategy for the treatment of renal fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“It is generally believed that the anti-inflammatory activity of IL-6 is mediated by classical signaling, whereas the proinflammatory property is mediated by the trans-signaling pathway [8].”
BackgroundInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 1×
“STAT3 is a transcription factor that regulates many downstream target genes [7].”
BackgroundInterleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643 · cited 2×
“Fc-linked gp130 is currently in clinical trials [16].”
BackgroundBlockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production
Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraishi, H., Iida, M., Kobayashi, T., & Yoshimura, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209281 · Cited by 246 · cited 1×
“It has also been reported that IL-6-STAT3 signaling enhances the expression of TGF-β1 to promote fibrosis [48].”
BackgroundNowell, M. A., Williams, A. S., Carty, S. A., Scheller, J., Hayes, A. J., Jones, G. W., Richards, P. J., Slinn, S., Ernst, M., Jenkins, B. J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.613 · Cited by 215
O'Donoghue, R. J. J., Knight, D. A., Richards, C. D., Prêle, C. M., Lau, H. L., Jarnicki, A. G., Jones, J., Bozinovski, S., Vlahos, R., Thiem, S., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100604 · Cited by 152 · cited 1×
“Activated STAT3 has been found to be an important transcription factor in the pathogenesis of pulmonary and kidney fibrosis [46, 47].”
Background
Cited by
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Lim, Y. J., Sidor, N. A., Tonial, N. C., Che, A., & Urquhart, B. L. (2021) · Toxins · doi:10.3390/toxins13020142 · Cited by 373
Kan, X., Wang, J., Li, Y., Li, D., Li, F., Huang, C., & Liu, P. (2026) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2025.115397 · Cited by 3
Metadata
- Authors
- Chen, W., Yuan, H., Cao, W., Wang, T., Chen, W., Yu, H., Fu, Y., Jiang, B., Zhou, H., Guo, H., & Zhao, X.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 9
- Issue
- 14
- Pages
- 3980-3991
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2949642899
- Cited by
- 195
- References
- 8
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation. https://app.cochat.ai/papers/10.7150/thno.32352
- The paper
- Chen, W., Yuan, H., Cao, W., Wang, T., Chen, W., Yu, H., Fu, Y., Jiang, B., Zhou, H., Guo, H., & Zhao, X. (2019). Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation. Theranostics. https://doi.org/10.7150/thno.32352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.